Fresenius Medical Care AG & Co. KGaA (ADR) (NYSE:FMS)

follows the market~~

Dialysis treatment will continue to expand

IBD

Regular profit gain over last several years continued through 2008. Expect improving profits to continue with expanding health care.

IS A PLUS

My company is working on the expansion of the Fresenius site in Ogden, Utah. In the simplest terms, there are now six lines producing the "fibers" used in the dialysis equipment. There are more lines to come, oh yes, there are more....which means there will be more production. This company is only growing, and I know this from first hand experience.

I've never been good at picks in the medical sector. I like this company for its investment in Renal Solutions, since I can't buy into Renal solutions directly. Here's a blurb about Renal Solutions:

The nature of our new approach -- using living cells as therapeutic agents -- argues for the feasibility of developing whole classes of new cell-based and tissue engineered therapies. The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine. The apparently successful use of living cells in this way validates our approach and should encourage others to investigate cell therapies for a range of disorders.

MOre services for the aging population. And the government still pays for dialysis; if they stop (not a chance) this stock may tank.

I work at a subsidiary of FMS, Spectra Labs. I have no inside info on financials But I like this company and its mission. They treat empolyees well and although we profit from the illness of others we provide important care to them. Our future has never seemed brighter!

Fresenius Medical is well positioned to benefit from its strong market position as a dialysis care provider and product maker. Not only is it the US market leader, it also is growing fast in emerging markets which see rising need for dialysis services.
The company's business model is not exposed to fluctuations in economic growth, and a recent de-rating of its multiples make the stock look like an interesting investment in the longer term.

Breaking out to new all time highs after a short period of consolation. Great play on the aging baby boomers and rise in Type II diabetes in this country (sorry for sounding like a rapacious capitalists). Expecting this stock to hit $60 by the end of the year and placing stop loss below the 200 Day Moving Average.

my #.1, 20 to 30% per year

It's been said. Lots of need with aging boomers and Type2 Diabetes (with resultant renal failure) rising. Small risk that payments may get sqeezed in the future. And safe if the bears take hold. I've actually owned it for a few years in one of my retirement portfolios and it continues to do well. (I like to have stocks that I can leave for decades untouched in there.)

My sister-in-law has a small dialysis care company that outsources dialysis nurses. Apparently, all of the equipment they use is Fresenius. She's very happy with the products and the service she's had from them. That got me interested, and after looking over the fundamentals, I bought some shares for my actual portfolio.
Also, this is the largest company that I have in my real portfolio right now.

Industry Leader in a field that will only grow in the future. Self sufficient company.

Largest provider of dialysis supplies and services. Nearly self-sufficient company that relies very little on others for services, supplies, or equipment.

Fresenius is the largest provider of dialysis services through their clinics. Thye ill continue to do well.

Largest dialysis solutions provider in the World. Kidney failure is steadily on the rise and will continue until well into the 21st Century. Double Digit growth in their numbers from the top line all the way to EPS (per ADS for US Citizens). It is an AG based out of Germany. They are in acquisition mode and growth...growth...growth is there for the taking. It will make me and many others richer because of the need for dialysis worldwide.